Janssen study shows heart failure benefits of Invokana

Janssen has announced the findings of a new clinical study that demonstrates the heart health benefits associated with its drug Invokana.

New analysis of data from the CANVAS study programme has shown that the canagliflozin therapy was able to significantly reduce the risk of cardiovascular death or hospitalisation for heart failure in patients with type 2 diabetes who were at a high cardiovascular risk.

In addition, the data confirmed that proportional effects of Invokana were comparable across a broad population of patients, including those with and without heart failure at baseline.

CANVAS represents the longest, largest and broadest completed cardiovascular outcomes programme of any sodium glucose cotransporter 2 (SGLT2) inhibitor to date, and was the first to assess the efficacy, safety and durability of Invokana in more than 10,000 patients.

Dr Robert Cuddihy, vice-president of medical affairs for cardiovascular and metabolism at Janssen, said: "This new analysis from the landmark CANVAS programme helps reinforce important additional clinical benefits of canagliflozin."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.